Cargando…
HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss
HER2-positive breast cancer (HER2+ BC) is an aggressive subtype with a poor prognosis. Although the antibody trastuzumab, which targets the HER2 growth factor receptor, has improved survival rates, patients often present with de novo resistance or acquire resistance after an initial response. Identi...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413028/ https://www.ncbi.nlm.nih.gov/pubmed/28463969 http://dx.doi.org/10.1371/journal.pone.0176778 |